Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …

Thyroid cancer has become more common in recent years all around the world. Many issues
still need to be urgently addressed in the diagnosis, treatment, and prognosis of thyroid …

Simple Summary Studies analyzing the protein profile of thyroid tissue in patients with
papillary thyroid cancer (PTC) have revealed disturbed metabolic pathways, including those …

Radioactive iodine (RAI) therapy with iodine-131 is performed in select cases of
differentiated thyroid cancer (DTC), typically for remnant ablation, adjuvant therapy, or …

The use of radioiodine therapy (RIT) is debated in intermediate-risk differentiated thyroid
cancer (DTC) patients. The understanding of the molecular mechanisms involved in the …

Background Acute sialadenitis is one of the major physical complications of radioactive
iodine therapy (RAIT) for differentiated thyroid cancer (DTC). It is considered necessary to …

Context Despite the wide revision of current guidelines, the management of papillary thyroid
microcarcinoma (mPTC) still has to be decided case by case. There is conflicting evidence …

Follicular thyroid carcinoma (FTC) is the second most common type of thyroid cancer,
presenting unique diagnostic and therapeutic challenges. This review provides a …

Purpose Cabozantinib is an oral multi-tyrosine kinase inhibitor (TKI) that has been approved
in Europe for advanced renal cell carcinoma, hepatocellular carcinoma, locally advanced …

Radioiodine refractory differentiated thyroid cancer (RR-DTC) is the main factor adversely
affecting the overall survival rate of patients with thyroid cancer. The aim of the present study …